Boehringer Hopes To Expand Product Line, Achieve 35 Percent Growth Rate In China
This article was originally published in PharmAsia News
With the addition of Sifrol (pramipexole), Spiriva (tiotropium peptide), and Micardis (telmisartan) to China's new health insurance directory, Boehringer Ingelheim became a big winner in the list's latest revision
You may also be interested in...
Dutch foot-care specialists TheOTCLab launches what it claims to be the world's first fungal nail plaster.
Suppliers to the UK’s National Health Service from outside the EU could save up to 12% during COVID-19 emergency measures as the UK tries to increase supplies
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.